Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  H. Lundbeck A/S    LUN   DK0010287234

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo H. Lundbeck A/S
Engages in the research, development, production and sale of pharmaceuticals for the treatment of brain diseases

H. Lundbeck A/S engages in the research, development, and market of pharmaceutical products for the treatment of psychiatric and neurological disorders.

It operates through the following geographical segments: Europe, the Unites States of America, and International Markets.

Its product portfolio targets the following diseases: Alzheimer's, depression, Parkinson's, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington's.

The company was founded by Hans Lundbeck on August 14, 1915 and is headquartered in Valby, Denmark.

Number of employees : 5 257 persons.
Sales per Businesses
20142015Delta
DKK (in Million)%DKK (in Million)%
Cipralex4,64734.5%---
Other Pharmaceuticals1,98514.7%---
Xenazine1,69512.6%---
Azilect1,49711.1%---
Ebixa1,0587.9%---
Onfi923.006.9%---
Sabril716.005.3%---
Other Revenue547.004.1%---
Treanda212.001.6%---
Brintellix188.001.4%---
Pharmaceuticals--14,594100.9%-
Sales per Regions
20142015Delta
DKK (in Million)%DKK (in Million)%
Rest of Europe4,99137.1%3,86926.7% -22.48%
International4,14430.8%3,82726.5% -7.65%
United States3,75827.9%6,35343.9% +69.05%
Other Revenue547.004.1%518.003.6% -5.3%
Denmark28.000.2%27.000.2% -3.57%
Managers
NameAgeSinceTitle
Kåre Schultz552015President & Chief Executive Officer
Lars Søren Rasmussen572013Chairman
Anders Götzsche492007CFO & Executive VP-Information Technology
Lars Bang541988EVP-Supply Operations & Engineering
Anders Gersel Pedersen MD, PhD652000Executive Vice President-Research & Development
Jørn Møller Mayntzhusen, MBA502002Director & Senior Manager-Supply Optimisation
Mona Elisabeth Elster541994Director
Terrie Curran472014Independent Director
Henrik Sindal Jensen, PhD472004Director
Lene Skole-Sørensen572015Deputy Chairman
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 197,619,721 59,643,877 30.2% 623,926 0.3% 30.2%
Shareholders
NameEquities%
Lundbeck Foundation 137,351,918 69.5%
Wellington Management Co. LLP 4,847,203 2.45%
OppenheimerFunds, Inc. 4,540,846 2.30%
TIAA-CREF Investment Management LLC 3,011,904 1.52%
Norges Bank Investment Management 1,963,697 0.99%
Teachers Advisors, Inc. 1,959,331 0.99%
Templeton Global Advisors Ltd. 1,819,347 0.92%
Oddo Meriten Asset Management SA 1,529,004 0.77%
Nordea Investment Management AB (Denmark) 1,312,859 0.66%
Janus Capital Management LLC 1,211,546 0.61%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Pharmaceuticals - NEC
Advertisement
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
H. LUNDBECK A/S13.68%7 587
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-19.61%188 878
NOVARTIS AG-19.07%178 737
MERCK & CO., INC.15.85%168 544
SANOFI-4.20%103 510
BRISTOL-MYERS SQUIBB C..-17.95%93 522
GLAXOSMITHKLINE PLC6.85%91 041
BAYER AG-25.06%76 831
ELI LILLY AND CO-20.34%74 748
ALLERGAN PLC-39.30%71 149
NOVO NORDISK A/S-40.49%68 352
ASTRAZENECA PLC-11.62%64 588
ABBOTT LABORATORIES-15.23%55 801
SHIRE PLC-3.05%52 210
TAKEDA PHARMACEUTICAL ..-22.03%32 564
ASTELLAS PHARMA INC-9.55%29 477
MYLAN NV-33.44%19 258
EISAI CO., LTD-16.80%17 197
SHIONOGI & CO LTD-2.08%16 452
Sector Pharmaceuticals - NEC
H. Lundbeck A/S : Connections
9 Ottiliavej
DK 2500 Valby, Copenhagen
Denmark

Phone : +45 36 30 13 11
Fax : +45 36 30 19 40
Internet : http://www.lundbeck.com
Markets and indexes
- NASDAQ OMX nordic Kopenhagen
- Main Market Large
- OMXC 20 /
Stock Exchange Codes
- ISIN Code :  DK0010287234
- Bloomberg Code :  LUN:DC
- Reuters Code :  LUN.CO
- Datastream Code :  DK:LUND
© 2016 People , Fundamentals and Ownership    © 2016 Cofisem